Product Defect

Metformin Carcinogenic Contaminants Investigation

Posted on

Migliaccio & Rathod LLP is currently investigating manufacturers of the widely used diabetes drug metformin, known by the common brand names Glucofage, Riomet, and Glumetza, for product contamination. Online pharmacy Valisure tested various metformin batches for impurities containing N-nitrosodimethylamine, or NDMA, a probable human carcinogen, and found sixteen contaminated batches. One batch contained sixteen times […]

Product Defect

Ranitidine Carcinogenic Contaminants Investigation

Posted on

Migliaccio & Rathod LLP is currently investigating manufacturers of the prescription and over-the-counter heartburn medication ranitidine, known by the brand name Zantac. The U.S. Food and Drug Administration (FDA) recently requested manufacturers pull the drug from the market, citing an ongoing investigation that found many ranitidine samples contained hazardous levels of the contaminant NDMA, a […]

Environmental

Ethylene Oxide Emissions Investigation

Posted on

Migliaccio & Rathod LLP is currently investigating chemical plants across the United States that emit ethylene oxide into the air, despite the known public health risks of doing so. Ethylene oxide is commonly used as a sterilizing agent for medical equipment, and as an intermediate in chemical manufacturing. Although long considered hazardous, the Environmental Protection […]

Product Defect

Valsartan Carcinogenic Contaminants Investigation

Posted on

Migliaccio & Rathod LLP has filed a class action lawsuit against certain manufacturers of Valsartan, an angiotensin II receptor blocker used to treat high blood pressure and heart failure. The Food and Drug Administration issued a recall of Valsartan because it contained significant levels of N-nitrosodimethylamine (NDMA)—a probable human carcinogen—the long-term exposure of which increases […]